Daily intake of phosphodiesterase type 5 inhibitors - correction of erectile dysfunction and lower urinary tract symptoms in patients with bph
- Authors: Volkov A.A1, Petrichko M.I2, Budnik N.V1
-
Affiliations:
- SBI "Hospital for War Veterans"
- Central Clinical Hospital № 2 n.a. N.A. Semashko of the JSC Russian Railways
- Issue: No 4 (2014)
- Pages: 64-68
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280248
- ID: 280248
Cite item
Open Access
Access granted
Abstract
Research included 88 patients with benigh prostate hyperplasia (BPH) and the erectile dysfunction (ED). Depending on received conservative therapy patients were divided into three groups. The patients of the 1st group were treated with dutasteride 0.5 mg, tamsulosin 0.4 mg and tadalafil 5 mg, in group 2 patients received dutasteride 0.5 mg and 5 mg tadalafil, in the third group of patients received dutasteride 0.5 mg and tamsulosin 0.4 mg daily. The efficiency of treatment was estimated by patients’ questionnaire before treatment and after 12 weeks of therapy. The analysis of the received results showed the expediency of use of tadalafil 5 mg for daily dose in the scheme of treatment of patients with BPH and ED. When using tadalafil 5 mg was obtained comparable to tamsulosin decrease the symptoms of lower urinary tract and simultaneous improvement in erectile function. It is concluded that in certain groups of patients with BPH and ED may use tadalafil 5 mg with dutasteride without combination with α1-blockers.
Full Text
About the authors
A. A Volkov
SBI "Hospital for War Veterans"
Email: Volkov73a@bk.ru
PhD in Medical Sciences, Head of Urological Department at the SBI "Hospital for War Veterans " Rostov-on-Don
M. I Petrichko
Central Clinical Hospital № 2 n.a. N.A. Semashko of the JSC Russian RailwaysMoscow
N. V Budnik
SBI "Hospital for War Veterans"Rostov-on-Don
References
- Gacci M. et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep. 2013; 8: 150-159.
- Gacci M. et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011; 60: 809-825.
- Mondut A.M., Rimm E.B., Giovannucci E. et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol. 2008; 179 (6): 2321-2326.
- Brock G.B., McVary K.T., Roehrborn C.G. et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol. 2014; Feb; 191(2): 405-411.
- Gacci M.I., Corona G., Satvi M. et al. A systematic review and metaanalysis on the use of phosphodiesterase 5 inhibitors alone or in combination with а-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012; May; 61(5): 994- 1003.
- Giutiano F.I., Oetke M., Jungwirth A. et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week doubleblind study. J Sex Med. 2013; Mar; 10(3): 857-865.
- Porst H., McVary K.T., Montorsi F. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009; Oct; 56(4): 727-735.
- Oetke M., Giutiano F., Mirone V. et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 2012; May; 61(5): 917-925.
- Oetke M.I., Giutiano F., Baygani S.K. et al. Treatment Satisfaction with Tadalafil or Tamsulosin versus Placebo in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results from a Randomized, Placebo-controlled Study. BJU Int. 2014; Mar 10.
- Casabé A., Roehrborn C.G., Da Pozzo L.F. et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014; Mar; 191(3): 727-733.
- Park H.J., Park N.C. Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasia. Eur Urol Suppl. 2013; 12; e1092.
Supplementary files
